CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Cefixime

头孢克肟 杂质对照品Cefixime Impurities

EP25 个杂质条目25 impurity entries

本页汇总 头孢克肟 的 25 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 25 impurity reference standards of Cefixime with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 头孢克肟(Cefixime)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesDetermination of Cefixime by a Validated Stability-Indicating HPLC Method and Identification of its Related Substances by LC-MS/MS Studies
    Scientia pharmaceutica · 2013 · Talebpour Z et al.  ·  PMID 23833715  ·  DOI
  2. 杂质研究Impurity studiesValidated stability-indicating spectrophotometric methods for the determination of cefixime trihydrate in the presence of its acid and alkali degradation products
    Journal of AOAC International · 2015 · Mostafa NM et al.  ·  PMID 25857876  ·  DOI
  3. 杂质研究Impurity studiesPredictive analytical workflow for rapid structure elucidation and in silico toxicological qualification of an unidentified impurity in cefixime granules for oral suspension
    Acta pharmaceutica (Zagreb, Croatia) · 2026 · Mitrevska I et al.  ·  PMID 41885693  ·  DOI
  4. 分析方法Analytical MethodsSimultaneous determination of cefixime and erdosteine in combined dosage form using validated spectrophotometric methods
    Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy · 2020 · Mahrouse MA et al.  ·  PMID 32652285  ·  DOI
  5. 分析方法Analytical MethodsBioanalytical method development and validation for simultaneous estimation of cefixime and dicloxacillin by RP-HPLC in human plasma
    Acta chimica Slovenica · 2014 · Bhinge SD et al.  ·  PMID 25286213

头孢克肟 —— 原料药与杂质对照品Cefixime — drug substance & impurities

共 26 个条目(含原料药本体)26 items incl. the drug substance
Cefixime structure
EP原料药 APIAPI
头孢克肟Cefixime
Cefixime
CAS No.79350-37-1
Chemical FormulaC16H15N5O7S2
Purity>95%询价On request
10mg25mg50mg100mg
Cefixime Impurity 3(Cefixime EP Impurity A) structure
EPA
头孢克肟杂质3(头孢克肟EP杂质A)Cefixime Impurity 3(Cefixime EP Impurity A)
Cefixime Impurity 3(Cefixime EP Impurity A)
CAS No.1614255-90-1
Chemical FormulaC16H17N5O8S2
Purity>95%询价On request
10mg25mg50mg100mg
Cefixime Impurity 1(Cefixime EP Impurity C) structure
EPC
头孢克肟杂质1(头孢克肟EP杂质C)Cefixime Impurity 1(Cefixime EP Impurity C)
Cefixime Impurity 1(Cefixime EP Impurity C)
CAS No.108691-83-4
Chemical FormulaC16H15N5O7S2
Purity>95%询价On request
10mg25mg50mg100mg
Cefixime Impurity 4(Cefixime EP Impurity D) structure
EPD
头孢克肟杂质4(头孢克肟EP杂质D)Cefixime Impurity 4(Cefixime EP Impurity D)
Cefixime Impurity 4(Cefixime EP Impurity D)
CAS No.97164-56-2
Chemical FormulaC16H15N5O7S2
Purity>95%询价On request
10mg25mg50mg100mg
Cefixime Impurity 5(Cefixime EP Impurity E) structure
EPE
头孢克肟杂质5(头孢克肟EP杂质E)Cefixime Impurity 5(Cefixime EP Impurity E)
Cefixime Impurity 5(Cefixime EP Impurity E)
CAS No.72701-01-0
Chemical FormulaC15H15N5O7S2
Purity>95%询价On request
10mg25mg50mg100mg
Cefixime Impurity 6(Cefixime EP Impurity F) structure
EPF
头孢克肟杂质6(头孢克肟EP杂质F)Cefixime Impurity 6(Cefixime EP Impurity F)
Cefixime Impurity 6(Cefixime EP Impurity F)
CAS No.79368-95-9
Chemical FormulaC18H19N5O7S2
Purity>95%询价On request
10mg25mg50mg100mg
Cefixime Impurity 7 structure
7
头孢克肟杂质7Cefixime Impurity 7
Cefixime Impurity 7
CAS No.88621-01-6
Chemical FormulaC17H17N5O7S2
Purity>95%询价On request
10mg25mg50mg100mg
Cefixime Impurity 8(Sulfone) structure
8
头孢克肟杂质8砜Cefixime Impurity 8(Sulfone)
Cefixime Impurity 8(Sulfone)
CAS No.2682217-22-5
Chemical FormulaC16H15N5O9S2
Purity>95%询价On request
10mg25mg50mg100mg
Cefixime Impurity 12 structure
12
头孢克肟杂质12(头孢克肟氧化杂质)Cefixime Impurity 12
Cefixime Impurity 12
CAS No.1335555-87-7
Chemical FormulaC16H15N5O8S2
Purity>95%现货In stock
10mg25mg50mg100mg
Cefixime Impurity 18 structure
18
头孢克肟杂质18Cefixime Impurity 18
Cefixime Impurity 18
CAS No.1614255-93-4
Chemical FormulaC15H17N5O6S2
Purity>95%询价On request
10mg25mg50mg100mg
Cefixime Impurity 23 structure
23
头孢克肟杂质23Cefixime Impurity 23
Cefixime Impurity 23
CAS No.79368-92-6
Chemical FormulaC20H23N5O7S2
Purity>95%询价On request
10mg25mg50mg100mg
Cefixime Impurity 32 structure
32
头孢克肟杂质32Cefixime Impurity 32
Cefixime Impurity 32
CAS No.246035-38-1
Chemical FormulaC15H12N4O4S3
Purity>95%询价On request
10mg25mg50mg100mg
Cefixime Impurity 37 structure
37
头孢克肟杂质37Cefixime Impurity 37
Cefixime Impurity 37
CAS No.2488905-73-1
Chemical FormulaC16H15N5O7S2
Purity>95%询价On request
10mg25mg50mg100mg
Cefixime Impurity 39 structure
39
头孢克肟杂质39Cefixime Impurity 39
Cefixime Impurity 39
CAS No.80544-17-8
Chemical FormulaC8H9N3O5S
Purity>95%询价On request
10mg25mg50mg100mg
Cefixime Impurity 43 structure
43
头孢克肟杂质43Cefixime Impurity 43
Cefixime Impurity 43
CAS No.1093856-59-7
Chemical FormulaC17H17N5O7S2
Purity>95%询价On request
10mg25mg50mg100mg
Cefixime Impurity 52 structure
52
头孢克肟杂质52Cefixime Impurity 52
Cefixime Impurity 52
CAS No.1335475-19-8
Chemical FormulaC15H17N5O6S2
Purity>95%询价On request
10mg25mg50mg100mg
Cefixime Impurity 56 structure
56
头孢克肟杂质56Cefixime Impurity 56
Cefixime Impurity 56
CAS No.33748-00-4
Chemical FormulaC17H16N2O4S
Purity>95%询价On request
10mg25mg50mg100mg
Cefixime Impurity 67 structure
67
头孢克肟杂质67Cefixime Impurity 67
Cefixime Impurity 67
CAS No.2489879-10-7
Chemical FormulaC17H19N5O8S2
Purity>95%询价On request
10mg25mg50mg100mg
Cefixime Impurity 76 structure
76
头孢克肟杂质76Cefixime Impurity 76
Cefixime Impurity 76
CAS No.1469982-17-9
Chemical FormulaC15H17N5O6S2
Purity>95%询价On request
10mg25mg50mg100mg
Cefixime Impurity 78 structure
78
头孢克肟杂质78Cefixime Impurity 78
Cefixime Impurity 78
CAS No.74440-01-0
Chemical FormulaC9H11N3O5S
Purity>95%询价On request
10mg25mg50mg100mg
Cefixime Impurity 80 structure
80
头孢克肟杂质80Cefixime Impurity 80
Cefixime Impurity 80
CAS No.124329-31-3
Chemical FormulaC25H26N2O6S
Purity>95%询价On request
10mg25mg50mg100mg
Cefixime Impurity 84 structure
84
头孢克肟杂质84Cefixime Impurity 84
Cefixime Impurity 84
CAS No.2311847-19-3
Chemical FormulaC14H10N4O4S3
Purity>95%询价On request
10mg25mg50mg100mg
Cefixime Impurity 85 structure
85
头孢克肟杂质85Cefixime Impurity 85
Cefixime Impurity 85
CAS No.119636-62-3
Chemical FormulaC42H38N2O5PS+·I-
Purity>95%询价On request
10mg25mg50mg100mg
Cefixime Impurity 86 structure
86
头孢克肟杂质86Cefixime Impurity 86
Cefixime Impurity 86
CAS No.101156-41-6
Chemical FormulaC24H23BrN2O5S
Purity>95%询价On request
10mg25mg50mg100mg
Cefixime Impurity 87 structure
87
头孢克肟杂质87Cefixime Impurity 87
Cefixime Impurity 87
CAS No.74440-02-1
Chemical FormulaC11H15N3O5S
Purity>95%询价On request
10mg25mg50mg100mg
Cefixime Impurity 88 structure
88
头孢克肟杂质88Cefixime Impurity 88
Cefixime Impurity 88
CAS No.84080-70-6
Chemical FormulaC7H8ClNO6
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

头孢克肟 —— 研究文献与合成路线Cefixime — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 头孢克肟 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Cefixime. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Study of degradation profile and development of stability indicating methods for cefixime trihydrate
    Gandhi SP, Rajput SJ · Indian journal of pharmaceutical sciences · 2009 · 被引 4cited 4
  2. Validated stability-indicating spectrophotometric methods for the determination of cefixime trihydrate in the presence of its acid and alkali degradation products
    Mostafa NM, Abdel-Fattah L, Weshahy SA, et al. · Journal of AOAC International · 2015 · 被引 7cited 7
  3. Efficient degradation and detoxification of the emerging pollutants antibiotics including sulfonamides and cefixime by the LAC-48-2 laccase/mediator system
    Deng W, Wu X, Hu Z, et al. · Journal of hazardous materials · 2026
  4. Efficient Biodegradation of Cefixime by the Newly Isolated Strain <i>Pseudochrobactrum asaccharolyticum</i> TY12 and Insights into Its Degradation Mechanism
    Kou B, Wang Z, Wang Y, et al. · Journal of agricultural and food chemistry · 2026
  5. Spectrofluorimetric method for determination and validation of cefixime in pharmaceutical preparations through derivatization with 2-cyanoacetamide
    Shah J, Jan MR, Shah S, et al. · Journal of fluorescence · 2011 · 被引 19cited 19
  6. Anodic voltammetric behavior and determination of cefixime in pharmaceutical dosage forms and biological fluids
    Golcu A, Dogan B, Ozkan SA · Talanta · 2005 · 被引 23cited 23

合成与制备工艺专利Synthesis & process patents

  1. Process for preparing cefixime
    XIANBO CHENG, LIPENG HU, SHUXIANG YE, CHENGMIAO XU, et al. · 公开号 CN101319246CN101319246 · 2008
  2. PROCESS FOR THE PREPARATION OF CEFIXIME
    TYAGI OM DUTT, RANE DNYANDEO RAGHO, MAHAJAN SANJAY, CHAVAN YUVRAJ ATMARAM · 公开号 MX2007007476MX2007007476 · 2007
  3. PROCESS FOR THE PREPARATION OF CEFIXIME
    TYAGI OM DUTT, RANE DNYANDEO RAGHO, MAHAJAN SANJAY, CHAVAN YUVRAJ ATMARAM · 公开号 WO2006067806WO2006067806 · 2006
  4. PROCESS FOR THE PREPARATION OF CEFIXIME
    TYAGI OM DUTT, RANE DNYANDEO RAGHO, MAHAJAN SANJAY, CHAVAN YUVRAJ ATMARAM · 公开号 EP1828206EP1828206 · 2007
  5. Cefixime compound and preparation method thereof
    XIANFENG ZHENG · 公开号 CN101544660CN101544660 · 2009

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

头孢克肟 杂质谱研究要点Cefixime — impurity profiling notes

下面这些是拿到 头孢克肟 的 26 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 26 impurity entries for Cefixime, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances